The novel approaches in the treatment of advanced castration-resistant prostate cancer (CRPC)

Vladimir Mouraviev
Associated Medical Professionals of NY, USA

Introduction of new drug developments for CRPC has revolutionized the treatment outcomes of this desperated disease. For the past 3 year FDA approved more drugs than in previous few decades with additional drugs coming up. This required a significant adjustment in clinical structural and treatment armamentarium approaches. The clinical database of 633 patients undergoing a different kinds of androgen deprivation therapy (ADT) was created in order to optimize a treatment efficacy of new drugs approved by FDA or under development phase as a clinical trials. The integrative sequencing protocol for patients with advanced prostate cancer has developed based on individual approach of tumor tissue signatures of biopsy cores or prostatectomy specimens, biomarker-defined clinical trials and treatments, and improved outcomes. Amongst novel pipelines that have been recently introduced in our specialized clinic the main ones included the following: new anti-androgens such CYP17 inhibitors (enzalutimide, abiraterone etc.), immunotherapy (Sipuleucil-T alone and in combinations), bone-targeted therapy (denosumab, Radium-223). While initial results of monotherapy demonstrated an encouraging results, the sequence and use of different combination approaches remain to be established upon collection of more robust clinical data and conduction of randomized clinical trials.

Biography

Vladimir Mouraviev has completed his M.D. at the age of 22 years from Kirov State Medical Academy in St.Peteresburg, Russia. He also completed a Ph.D. in uropathology at age of 29 years. Vladimir is the director of clinical research at large urology Associate Medical Professionals group in Syracuse, NY. He has published more than 100 papers in reputed journals and serving as ad-hoc reviewer of seven peer-reviewed urological journals.